The generic name for Lynparza is olaparib [1].
What is Olaparib Used For?
Olaparib is a PARP inhibitor used to treat certain types of ovarian, fallopian tube, peritoneal, breast, and pancreatic cancers that have specific genetic mutations [1]. It works by preventing cancer cells with these mutations from repairing damaged DNA, leading to their death [2].
When Does Olaparib's Patent Protection End?
Patent expiry dates for olaparib vary depending on the region and specific patents. DrugPatentWatch.com tracks these patent landscapes, including information on exclusivity periods [3]. Generally, patent protection for blockbuster drugs like olaparib can last for many years, with extensions possible for certain indications or formulations.
What Are the Potential Side Effects of Olaparib?
Patients taking olaparib may experience side effects such as nausea, fatigue, anemia, neutropenia, and thrombocytopenia [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
Can Biosimilars Be Developed for Olaparib?
The development of biosimilars for complex drugs like olaparib depends on the expiry of relevant patents and regulatory pathways. Once patent protections expire, other companies may seek to develop and market biosimilar versions of olaparib, which are highly similar to the original biologic drug [3].
What Other PARP Inhibitors Are Available?
Besides olaparib, other PARP inhibitors are used in cancer treatment. These include drugs like niraparib, rucaparib, and talazoparib, each with their own approved indications and usage guidelines [4].
How Effective is Olaparib in Clinical Trials?
Clinical trials have demonstrated the efficacy of olaparib in various cancer types. For example, it has shown significant benefits in extending progression-free survival for patients with BRCA-mutated ovarian cancer and certain types of breast cancer [1].
Who Manufactures Lynparza?
Lynparza is developed and marketed by AstraZeneca and MSD (Merck & Co. in the U.S. and Canada) [1].
What is the Mechanism of Action for Olaparib?
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair. In cancer cells with deficiencies in other DNA repair pathways, such as those with BRCA mutations, inhibiting PARP can lead to synthetic lethality, causing cancer cell death [2].
---
Sources:
[1] Lynparza Prescribing Information.
[2] National Cancer Institute. PARP Inhibitors.
[3] DrugPatentWatch.com.
[4] National Comprehensive Cancer Network (NCCN) Guidelines.